CHDM clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
DMCRN-02-001: Assessing Pediatric Endpoints in DM1
open to eligible people ages up to 59 months
The overall goal of the study is to establish valid clinical endpoint assessments for children with congenital myotonic dystrophy type 1 and childhood myotonic dystrophy type 1, and develop biomarkers for the condition.
at UCLA
Our lead scientists for CHDM research studies include Perry Shieh, MD, PhD.
Last updated: